Customize your JAMA Network experience by selecting one or more topics from the list below.
In the Invited Commentary, “Evaluating Risks and Benefits of Evolving Systemic Treatments of Neuroendocrine Tumors,” published online in the February 14, 2019, issue of JAMA Oncology,1 the following omitted additional information has been added: “Dr Strosberg reports that he was invited to contribute unpublished data to this meta-analysis (reference 3)2 in 2017 but was unable to do so.” This article was corrected online.
Omission in Additional Information. JAMA Oncol. 2019;5(4):580. doi:10.1001/jamaoncol.2019.0708
Create a personal account or sign in to: